Advertisement

Topics

Amgen's New Analyses Show Repatha Significantly Reduced Cardiovascular Events in Patients With Pe...

19:00 EST 13 Nov 2017 | BioSpace

These results highlight Repatha's ability to reduce the residual risk for CV events particularly in high-risk patients with limited treatment options.

Original Article: Amgen's New Analyses Show Repatha Significantly Reduced Cardiovascular Events in Patients With Pe...

NEXT ARTICLE

More From BioPortfolio on "Amgen's New Analyses Show Repatha Significantly Reduced Cardiovascular Events in Patients With Pe..."

Advertisement
Quick Search
Advertisement
Advertisement